Revenue Cycle Management Market worth $132.06 billion by 2031 - Exclusive Report by MarketsandMarkets™

MarketsandMarkets projects the global revenue cycle management market will grow from $73.61 billion in 2026 to $132.06 billion by 2031, a 12.4% CAGR, driven by value-based reimbursement, interoperability mandates and healthcare billing automation. AI-enabled RCM is expected to be the fastest-growing technology segment, with applications in coding, denial prevention, claims processing and payment forecasting. Investment and consolidation are accelerating: Candid Health raised $120 million in a July 2026 Series D, Adonis raised $40 million in March, and Waystar acquired Iodine for $1.25 billion in October 2025.

Analysis

This is not a near-term earnings catalyst; it is directionally supportive third-party market research whose growth estimates should not be underwritten as company guidance. The investable implication is that RCM spend is migrating from labor arbitrage toward denial prevention, coding automation and workflow orchestration. Vendors with embedded payer/provider connectivity and mission-critical transaction data should retain pricing power, while standalone point solutions face rising customer-acquisition costs and consolidation pressure from AI-native entrants.

WAY is the cleanest public read-through: incremental automation adoption can support durable transaction-volume growth and operating leverage, but its premium multiple leaves little tolerance for a deceleration in provider IT budgets or payment-volume growth. SOLV has potential upside if its health-information segment converts installed clinical documentation relationships into AI-RCM cross-sell; however, execution must show in segment organic growth and margin, not AI product announcements. UNH's Optum platform is strategically advantaged, but RCM remains too small relative to consolidated earnings to be a primary driver; the more relevant benefit is deeper provider workflow ownership and lower servicing costs.

Over 1-3 months, the key catalyst is evidence from WAY and SOLV bookings, net-revenue retention, and AI attach rates rather than broad TAM reports. Over 6-18 months, the likely second-order effect is lower demand for offshore/manual claims labor, pressuring CTSH's healthcare BPO mix unless it shifts revenue toward higher-value implementation and managed-AI services. Contrarian risk: AI may compress vendor pricing faster than it expands claim volumes, particularly where hospitals use automation to consolidate vendors; the winners will be platforms that can prove cash-collection lift, not merely workflow automation.

A material reversal would be visible in weaker provider capital budgets, an increase in implementation churn, or payer pushback that limits automated adjudication. For WAY, watch quarterly transaction/revenue growth below the company's baseline and any sustained compression in adjusted EBITDA margin; for SOLV, watch Health Information Systems organic growth and evidence that AI investment is dilutive rather than cross-sell accretive.

Key Decisions for Investors

• Maintain a 6-12 month overweight in WAY versus CTSH as a pair trade: long WAY / short CTSH in equal dollar amounts. The thesis is platform transaction monetization and automation-led operating leverage versus labor-intensive services exposure; reassess if WAY's next two quarters show material volume deceleration or CTSH demonstrates healthcare-services margin expansion above guidance.
• Build a starter long in SOLV ahead of the next two earnings reports, sized modestly given execution risk. Upside requires Health Information Systems to translate AI-enabled coding/RCM adoption into accelerating organic growth and margin; exit if segment growth remains flat-to-down while investment expense rises.
• Do not add UNH solely for RCM exposure. Treat Optum workflow expansion as a secondary moat enhancer; use any position only within a broader managed-care thesis, with Medicare Advantage reimbursement/regulatory developments remaining the dominant risk.
• Place an alert on CTSH healthcare bookings, utilization and margin commentary over the next 1-3 quarters. A confirmed decline in manual RCM/BPO demand without offsetting AI transformation revenue would create a more actionable short or underweight signal than this market-research release alone.